JP2024543954A5 - - Google Patents

Info

Publication number
JP2024543954A5
JP2024543954A5 JP2024532354A JP2024532354A JP2024543954A5 JP 2024543954 A5 JP2024543954 A5 JP 2024543954A5 JP 2024532354 A JP2024532354 A JP 2024532354A JP 2024532354 A JP2024532354 A JP 2024532354A JP 2024543954 A5 JP2024543954 A5 JP 2024543954A5
Authority
JP
Japan
Prior art keywords
composition according
sars
recombinant
vaccine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543954A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080561 external-priority patent/WO2023102375A1/en
Publication of JP2024543954A publication Critical patent/JP2024543954A/ja
Publication of JP2024543954A5 publication Critical patent/JP2024543954A5/ja
Pending legal-status Critical Current

Links

JP2024532354A 2021-11-30 2022-11-29 Ｎａｎｔ ｃｏｖｉｄワクチン交差反応性 Pending JP2024543954A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284203P 2021-11-30 2021-11-30
US63/284,203 2021-11-30
PCT/US2022/080561 WO2023102375A1 (en) 2021-11-30 2022-11-29 Nant covid vaccine cross reactivity

Publications (2)

Publication Number Publication Date
JP2024543954A JP2024543954A (ja) 2024-11-26
JP2024543954A5 true JP2024543954A5 (https=) 2025-06-09

Family

ID=86613140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532354A Pending JP2024543954A (ja) 2021-11-30 2022-11-29 Ｎａｎｔ ｃｏｖｉｄワクチン交差反応性

Country Status (8)

Country Link
US (4) US11911459B2 (https=)
EP (1) EP4440614A4 (https=)
JP (1) JP2024543954A (https=)
KR (1) KR20240113521A (https=)
CN (1) CN118338912A (https=)
AU (1) AU2022400924A1 (https=)
CA (1) CA3236215A1 (https=)
WO (1) WO2023102375A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7692925B2 (ja) * 2020-03-11 2025-06-16 ナントセル，インコーポレイテッド Ｃｏｖｉｄ－１９の治療及びその方法
EP4118225A1 (en) * 2020-03-13 2023-01-18 The Johns Hopkins University Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms
CN115666634A (zh) * 2020-03-27 2023-01-31 瑞典疫苗制药有限公司 用于治疗和预防冠状病毒的组合物和方法
WO2021255270A1 (en) * 2020-06-19 2021-12-23 Ziphius Vaccines Self-amplifying sars-cov-2 rna vaccine

Similar Documents

Publication Publication Date Title
US12514918B2 (en) Nucleic acid molecules and uses thereof
US12403335B2 (en) Betacoronavirus MRNA vaccines
JP2017530124A5 (https=)
JP2017514483A5 (https=)
JP2017522907A5 (https=)
JP2008529558A5 (https=)
JP2019506175A5 (https=)
RU2008102930A (ru) Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки
JP2008522621A (ja) 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン
JP2020536489A5 (https=)
JP2004501646A5 (https=)
JP2008514203A5 (https=)
JP2024535145A5 (https=)
JP2020537525A (ja) 複製能力のあるアデノウイルスベクター
JP2024543954A5 (https=)
KR101329348B1 (ko) 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스
JP6373601B2 (ja) アカバネウイルスに対して中和活性を有する抗体を誘導するペプチド
AU2018275790B2 (en) Genetically attenuated nucleic acid vaccine
JP2010528603A (ja) ネコ抗原のアライグマポックスウイルス発現遺伝子
US20240318147A1 (en) Recombinant oncolytic virus, and construction method therefor and use thereof
RU2019113940A (ru) Мозаичные вакцины от вируса ящура серотипа а
JP2024523329A5 (https=)
Nag et al. The 2023 Nobel Prize in Physiology or Medicine.
WO2022033467A1 (zh) 构建溶瘤病毒的方法
Balar et al. Nonreplicating viral vectors for vaccine delivery